Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Fulgent Genetics
Deal Size : $100.0 million
Deal Type : Acquisition
Details : FID-007 consists of paclitaxel encapsulated in a polyethyloxazoline polymer excipient designed to enhance PK, biodistribution, and tolerability. The PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpe...
Product Name : FID-007
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Fulgent Genetics
Deal Size : $100.0 million
Deal Type : Acquisition
Reset All
